Cargando…

Gut Dysbiosis and Kidney Diseases

Gut dysbiosis is defined as disorders of gut microbiota and loss of barrier integrity, which are ubiquitous on pathological conditions and associated with the development of various diseases. Kidney diseases are accompanied with gut dysbiosis and metabolic disorders, which in turn contribute to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Chujin, Zhu, Han, Yao, Ying, Zeng, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927813/
https://www.ncbi.nlm.nih.gov/pubmed/35308555
http://dx.doi.org/10.3389/fmed.2022.829349
_version_ 1784670527294537728
author Cao, Chujin
Zhu, Han
Yao, Ying
Zeng, Rui
author_facet Cao, Chujin
Zhu, Han
Yao, Ying
Zeng, Rui
author_sort Cao, Chujin
collection PubMed
description Gut dysbiosis is defined as disorders of gut microbiota and loss of barrier integrity, which are ubiquitous on pathological conditions and associated with the development of various diseases. Kidney diseases are accompanied with gut dysbiosis and metabolic disorders, which in turn contribute to the pathogenesis and progression of kidney diseases. Microbial alterations trigger production of harmful metabolites such as uremic toxins and a decrease in the number of beneficial ones such as SCFAs, which is the major mechanism of gut dysbiosis on kidney diseases according to current studies. In addition, the activation of immune responses and mitochondrial dysfunction by gut dysbiosis, also lead to the development of kidney diseases. Based on the molecular mechanisms, modification of gut dysbiosis via probiotics, prebiotics and synbiotics is a potential approach to slow kidney disease progression. Fecal microbiota transplantation (FMT) and genetic manipulation of the gut microbiota are also promising choices. However, the clinical use of probiotics in kidney disease is not supported by the current clinical evidence. Further studies are necessary to explore the causal relationships of gut dysbiosis and kidney diseases, the efficiency and safety of therapeutic strategies targeting gut-kidney axis.
format Online
Article
Text
id pubmed-8927813
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89278132022-03-18 Gut Dysbiosis and Kidney Diseases Cao, Chujin Zhu, Han Yao, Ying Zeng, Rui Front Med (Lausanne) Medicine Gut dysbiosis is defined as disorders of gut microbiota and loss of barrier integrity, which are ubiquitous on pathological conditions and associated with the development of various diseases. Kidney diseases are accompanied with gut dysbiosis and metabolic disorders, which in turn contribute to the pathogenesis and progression of kidney diseases. Microbial alterations trigger production of harmful metabolites such as uremic toxins and a decrease in the number of beneficial ones such as SCFAs, which is the major mechanism of gut dysbiosis on kidney diseases according to current studies. In addition, the activation of immune responses and mitochondrial dysfunction by gut dysbiosis, also lead to the development of kidney diseases. Based on the molecular mechanisms, modification of gut dysbiosis via probiotics, prebiotics and synbiotics is a potential approach to slow kidney disease progression. Fecal microbiota transplantation (FMT) and genetic manipulation of the gut microbiota are also promising choices. However, the clinical use of probiotics in kidney disease is not supported by the current clinical evidence. Further studies are necessary to explore the causal relationships of gut dysbiosis and kidney diseases, the efficiency and safety of therapeutic strategies targeting gut-kidney axis. Frontiers Media S.A. 2022-03-03 /pmc/articles/PMC8927813/ /pubmed/35308555 http://dx.doi.org/10.3389/fmed.2022.829349 Text en Copyright © 2022 Cao, Zhu, Yao and Zeng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Cao, Chujin
Zhu, Han
Yao, Ying
Zeng, Rui
Gut Dysbiosis and Kidney Diseases
title Gut Dysbiosis and Kidney Diseases
title_full Gut Dysbiosis and Kidney Diseases
title_fullStr Gut Dysbiosis and Kidney Diseases
title_full_unstemmed Gut Dysbiosis and Kidney Diseases
title_short Gut Dysbiosis and Kidney Diseases
title_sort gut dysbiosis and kidney diseases
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927813/
https://www.ncbi.nlm.nih.gov/pubmed/35308555
http://dx.doi.org/10.3389/fmed.2022.829349
work_keys_str_mv AT caochujin gutdysbiosisandkidneydiseases
AT zhuhan gutdysbiosisandkidneydiseases
AT yaoying gutdysbiosisandkidneydiseases
AT zengrui gutdysbiosisandkidneydiseases